New gonorrhoea treatment hailed as breakthrough in fight against drug resistance
Scientists have hailed a new antibiotic treatment for gonorrhoea, the first in three decades, which they said could help combat the global rise of drug-resistant infections.
The sexually transmitted infection can result in serious complications if it is not treated promptly, especially for women, for whom it can lead to increased risks of ectopic pregnancy and infertility.
Cases of drug-resistant gonorrhoea have increased rapidly in recent years, reducing the options for treatment. There is an urgent need for new treatments for gonorrhoea, with no new antibiotics found since the 1990s.
Now a study has suggested that gepotidacin, an antibiotic used to treat urinary tract infections, could be used to fight the infection, ward off drug-resistant cases and improve patient experiences.
The phase-three results of the randomised control trial were published in the Lancet journal and presented at the annual European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna, Austria, on Monday. The trial was led by UK and US researchers and involved patients from the UK, US, Australia, Germany, Mexico and Spain
In the study of 622 patients, researchers compared gepotidacin, taken as a pill, with the standard treatment of ceftriaxone, an injection, and azithromycin, a pill.
They found the new pill to be as effective as the standard treatment at tackling the infection.
Crucially, gepotidacin was effective against strains of the gonorrhoea bacteria that are resistant to existing antibiotics. There were no treatment-related severe or serious side-effects for those treated with either medication, the Lancet reported.
The investigators said the new treatment could be an important tool in combatting the rise of gonorrhoea strains that are becoming resistant to the standard treatment. Additionally, treatment as a pill alone without the need for an injection would probably improve patient experiences and reduce the required healthcare resources.
The authors said gepotidacin 'demonstrated non-inferiority to ceftriaxone plus azithromycin' and offered a 'novel oral treatment option for uncomplicated urogenital gonorrhoea'.
They added: 'Gepotidacin is a novel oral antibacterial treatment with the potential to become an alternative option for the treatment of gonococcal infections.'
The authors also cautioned that the study looked primarily at urogenital gonorrhoea and that most of the patients were white men. Therefore more research was needed to see the impact of the treatment on gonorrhoea of the rectum and throat, and in women, children, and patients of other ethnicities.
Gonorrhoea is becoming increasingly resistant to antibiotics, with health officials previously warning it could be untreatable in the future.
Last year officials in England issued a warning about a rise in super-strength cases.
There were 85,000 cases of gonorrhoea diagnosed in England in 2023, the highest level since records began in 1918.
The vast majority of cases can be treated. But there has been an increase in people diagnosed with strands that are resistant to ceftriaxone, the 'first line' antibiotic typically used to treat the infection.
Most of those affected in England were in their 20s, heterosexual, and acquired the infection abroad, though some had no travel history, the UK Health Security Agency (UKHSA) said.
Global health leaders have previously warned that antimicrobial resistance poses a significant threat to humanity, with data showing it has become a leading cause of death worldwide and is killing about 3,500 people every day.
More than 1.2 million – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections, according to a comprehensive 2022 estimate of the global impact of antimicrobial resistance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
7 days ago
- The Guardian
Millions in west do not know they have aggressive fatty liver disease, study says
More than 15 million people in the US, UK, Germany and France do not know they have the most aggressive form of fatty liver disease, according to research. Metabolic dysfunction-associated steatotic liver disease (MASLD) – the formal name for non-alcoholic fatty liver disease – occurs in people who drink no or minimal amounts of alcohol whose liver contains more than 5% fat. Around two-thirds of patients with type 2 diabetes are thought to have the condition, which is also associated with obesity, heart and circulatory disease. Around 5% of adults globally have the most aggressive form of MASLD. Metabolic dysfunction-associated steatohepatitis (MASH) causes fibrosis (scarring) and can lead to cirrhosis and is linked to greater risk of cardiovascular disease, chronic kidney disease and liver cancer. But the vast majority of people do not know they have the condition. An international group of researchers examined prevalence and diagnosis of aggressive fatty liver disease in the US, UK, Germany and France. The researchers found that just under 3% of people in the UK, France and Germany, and 4% of those in the US have MASH, but diagnosis rates were below 18%. That means about 20 million people in the US, UK, Germany and France are living with MASH but only 2.5 million people have a diagnosis, leaving more than three-quarters – about 16.7 million people – unaware they have the condition. The report, published in the Lancet Regional Health Europe and presented at an the meeting of the global thinktank on steatotic liver disease in Barcelona, Spain on Thursday, calls for a doubling in diagnosis rates from 2022 levels. Traditionally, MASH was diagnosed through biopsy, but now non-invasive methods, such as blood tests, ultrasound and MRI scans can be used. As a result, everyone with type 2 diabetes; obesity combined with one or more other risk factors; and those with persistently high liver enzymes should be screened for MASH, the researchers conclude. Dr Jeffrey Lazarus, the lead author of the paper and a professor of global health in New York and Barcelona, said: 'Undiagnosed MASH costs economies billions of pounds in lost productivity and poor health. Unless diagnosis rates are doubled, alongside similar increases in treatment and care, direct health costs alone are predicted to triple over the next 20 years.' Responding to the findings, Emmanouil Tsochatzis, a professor of hepatology at UCL and a consultant hepatologist at the Royal Free hospital, said: 'More than 15 million people across the US and Europe have the deadliest form of fatty liver disease – and don't know it. Without faster diagnosis and access to treatment, the human and economic toll will skyrocket.' The research has also prompted renewed calls for weight loss jabs to be used to treat MASH. Dr Paul Brennan, a co-author of the Lancet paper and a hepatologist at NHS Tayside, said: 'GLP-1s (including Wegovy and Mounjaro) offer the potential to resynchronise our metabolism, by introducing feelings of satiety – fullness – and delaying the time the stomach takes to empty. These effects often result in reduced calorie intake, and improvements in how the liver handles nutrients as a result of weight loss, thus reducing scar tissue formation in the liver.' Michael Betel, the president of the Fatty Liver Alliance, said: 'Too many people living with type 2 diabetes or obesity are never tested for MASH until it's too late. We need a huge increase in liver health assessments in patients living with these diseases, alongside lifestyle changes and for some, when appropriate, weight loss drugs to reduce blood sugar and appetite. While weight loss drugs weren't created to treat liver disease, trials suggest they could benefit multiple metabolic-related conditions, and improve our liver health.' Separately a study published on Wednesday found that the diabetes drug dapagliflozin, which reduces blood sugar levels, can also reduce fat levels and fibrosis in the liver.
The Independent
01-06-2025
- The Independent
Innovative treatment effective in patients with certain tumours, study suggests
An innovative treatment that reprogrammes immune cells to recognise and kill cancer has been shown to be effective on patients with certain tumours in a pioneering trial. CAR T-cell therapy is usually used to treat some types of blood cancer. It involves genetically modifying a patient's T cells – a type of white blood cell – in a lab, before returning them to the bloodstream. A new first of its kind trial explored the use of the treatment in patients with advanced stomach cancer and gastroesophageal junction (GEJ) cancer, which develops at the point where the oesophagus meets the stomach. The phase two study, led by researchers in China, included people diagnosed with advanced stomach or GEJ cancer which had not responded to two previous lines of treatment. Some 104 patients were earmarked for CAR T-cell therapy while 52 were given standard care, which included a selection of drugs chosen by their doctor. Those who had CAR T-cell therapy lived an average for 7.9 months, compared to 5.5 months with standard care. Patients who received the treatment also spent 3.3 months without their cancer progressing compared to 1.8 months in the standard group. Researchers said that the study is the 'first randomised controlled trial of CAR T-cell therapy in solid tumours globally' and shows the treatment 'resulted in a significant improvement in progression-free survival, with a manageable safety profile'. They added that the findings, published in the Lancet and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, support CAR T-cell therapy 'as a new third-line treatment' for patients with advanced stomach and GEJ cancer.
The Guardian
30-05-2025
- The Guardian
Parental intuition better at spotting child illness than vital signs, study finds
Parental intuition is more likely to predict critical illness among children than vital signs used to monitor health, according to a study that strengthens the case for families to have a right to a second opinion under Martha's rule being piloted in the NHS. Experts from Monash University in Melbourne, Australia, said parents should be treated as part of a child's care team in hospital after data on almost 190,000 emergency hospital visits involving children. The researchers found that prenatal concern was associated with a higher likelihood the child would need to be given help to breathe, or mechanical ventilation. The research, published in the Lancet's journal on Child and Adolescent Health, noted that in almost one in five cases (19.3%) parents raised concerns about deterioration before vital signs indicated that the child was deteriorating. It comes after the tragic case of Martha Mills, who developed sepsis after an injuring her pancreas when she fell off her bike. She died in 2021 when doctors ignored repeatedly the concerns of her parents about her deterioration while in hospital. A coroner ruled she would most likely have survived if doctors had identified the warning signs of her rapidly deteriorating condition and transferred her to intensive care earlier. A campaign by Martha's mother, Merope Mills, an editor at the Guardian, and her father, Paul Laity, led NHS hospitals to pilot Martha's rule, which gives patients and their loved ones the right to an urgent review of treatment. Last December, NHS England data showed the rule was having a 'transformative effect' in improving patient safety. In the Melbourne study, parents and carers were routinely asked: 'Are you worried your child is getting worse?' In 4.7% of cases parents said they were concerned their child was deteriorating. The research team found that parents' and carers' concerns were 'significantly' linked to the child being admitted to an intensive care unit (ICU). When parents raised concerns, children were four times more likely to need ICU care, compared with children of parents who did not express concern. They also found that parental concern was more strongly associated with ICU admission than abnormal vital signs were – including abnormal heart rate, abnormal breathing or blood pressure. This could mean that taking parents' views into account could lead to earlier treatment, they added. Overall, they found that children of caregivers who voiced concerns were 'more unwell, they were more likely to be admitted to an inpatient ward, and stayed in hospital almost three times as long'. One of the lead authors of the paper, Dr Erin Mills, from Monash University's School of Clinical Sciences at Monash Health, said: 'We know that parents are the experts in their children, but stories of parents not being heard, followed by devastating outcomes, are all too common. We wanted to change that.' She added: 'If a parent said they were worried, their child was around four times more likely to require intensive care. That's a signal we can't afford to ignore. 'Parents are not visitors – they are part of the care team. We want every hospital to recognise that and give parents permission, and power, to speak up.'
